Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04306146 · ClinicalTrials.gov registry record · Phase 1
Study of CAD-9303 in Subjects With Schizophrenia
A Phase 1 study of Schizophrenia, sponsored by Cadent Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
- 2
- Study locations
NCT04306146: Completed Phase 1 study of Schizophrenia, sponsored by Cadent Therapeutics.
NCT04306146 is a Phase 1 study of Schizophrenia that has completed, run by Cadent Therapeutics. The registered enrollment target is 103 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (53% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04306146, a Phase 1 study of Schizophrenia, has completed, sponsored by Cadent Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will consist of Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts that will be randomized, double-blind, and placebo-controlled to assess the safety, tolerability, and pharmacokinetics of CAD-9303. The first SAD cohort will be in healthy volunteer subjects. The remaining cohorts will be in participants with schizophrenia.
Primary Outcome
Incidence of Adverse Events
Conditions Studied
Interventions
- DRUG Placebos
- DRUG CAD-9303
Study Locations (2)
California
- Collaborative Neuroscience Research - Long Beach
New Jersey
- Hassman Research Institute - Marlton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2020-02-28 |
| Est. Completion | 2021-11-24 |
| Phase | Phase 1 |
What the finished NCT04306146 record still lists
NCT04306146 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebos is the first listed.
NCT04306146 reports a single indexed study location in California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04306146 about?
NCT04306146 is a clinical study titled "Study of CAD-9303 in Subjects With Schizophrenia". This study will consist of Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts that will be randomized, double-blind, and placebo-controlled to assess the safety, tolerability, and pharmacokinetics of CAD-9303. The first SAD cohort will be in healthy volunteer subjects. The remaini...
What is the current status of trial NCT04306146?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2020-02-28. Estimated completion is 2021-11-24.
What conditions does trial NCT04306146 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT04306146?
The interventions under investigation include: Placebos (DRUG), CAD-9303 (DRUG).
Who is sponsoring clinical trial NCT04306146?
This trial is sponsored by Cadent Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04306146 being conducted?
This trial has 2 study locations across California, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04306146's enrollment target sits among peer trials
103 138th of 315 higher than 178 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI